Abstract
Prevalence estimates of depression in AD vary greatly across studies, and a reliable result is crucial for further interventions. A systematic review and meta-analysis was conducted to identify the prevalence of depression in AD patients. We searched PubMed and Embase, followed by data extraction, quality assessment, prevalence estimates and subgroup analyses. A total of 63 studies were included in the review. The prevalences of depression were 12.7% (CI, 8.8-17.8) and 42% (CI, 38-45) according to the DSM criteria for major depression and the specific criteria for dementia respectively. Subgroup analyses stratified by case identification showed that the prevalences of population-based stud ies were 5% (CI: 2-15) and 35% (CI: 29-41) according to the DSM criteria and the specific criteria respectively, while those of single source were 17% (CI: 11-25) and 43% (CI: 37-49). Subgroup analyses stratified by MMSE score revealed that the prevalences of severe AD were 8% (CI: 5-15) and 48% (CI: 41-54) according to the DSM criteria and the specific criteria respectively, while those of mild AD were 14% (CI: 8-24) and 40% (CI: 32- 47). In conclusion, the prevalence of depression according to the DSM criteria was lower than that of the specific criteria. Prevalence estimates conducted in population-based studies were lower compared with those in single-source studies irrespective of the screening tools. Patients with severe AD tended to have higher prevalence of depression according to the specific criteria, while the trend was opposite according to the DSM criteria. Thus, different settings and diagnostic approaches should be taken into account before estimates of depression and further interventions.
Keywords: Alzheimer’s disease, depression, epidemiology, meta-analysis, prevalence, systematic review.
Current Alzheimer Research
Title:The Prevalence of Depression in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Volume: 12 Issue: 2
Author(s): Song Chi, Chong Wang, Teng Jiang, Xi-Chen Zhu, Jin-Tai Yu and Lan Tan
Affiliation:
Keywords: Alzheimer’s disease, depression, epidemiology, meta-analysis, prevalence, systematic review.
Abstract: Prevalence estimates of depression in AD vary greatly across studies, and a reliable result is crucial for further interventions. A systematic review and meta-analysis was conducted to identify the prevalence of depression in AD patients. We searched PubMed and Embase, followed by data extraction, quality assessment, prevalence estimates and subgroup analyses. A total of 63 studies were included in the review. The prevalences of depression were 12.7% (CI, 8.8-17.8) and 42% (CI, 38-45) according to the DSM criteria for major depression and the specific criteria for dementia respectively. Subgroup analyses stratified by case identification showed that the prevalences of population-based stud ies were 5% (CI: 2-15) and 35% (CI: 29-41) according to the DSM criteria and the specific criteria respectively, while those of single source were 17% (CI: 11-25) and 43% (CI: 37-49). Subgroup analyses stratified by MMSE score revealed that the prevalences of severe AD were 8% (CI: 5-15) and 48% (CI: 41-54) according to the DSM criteria and the specific criteria respectively, while those of mild AD were 14% (CI: 8-24) and 40% (CI: 32- 47). In conclusion, the prevalence of depression according to the DSM criteria was lower than that of the specific criteria. Prevalence estimates conducted in population-based studies were lower compared with those in single-source studies irrespective of the screening tools. Patients with severe AD tended to have higher prevalence of depression according to the specific criteria, while the trend was opposite according to the DSM criteria. Thus, different settings and diagnostic approaches should be taken into account before estimates of depression and further interventions.
Export Options
About this article
Cite this article as:
Chi Song, Wang Chong, Jiang Teng, Zhu Xi-Chen, Yu Jin-Tai and Tan Lan, The Prevalence of Depression in Alzheimer’s Disease: A Systematic Review and Meta-Analysis, Current Alzheimer Research 2015; 12 (2) . https://dx.doi.org/10.2174/1567205012666150204124310
DOI https://dx.doi.org/10.2174/1567205012666150204124310 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease
Current Alzheimer Research Impact of Diabetes on Vasculature: Focus on Nervous System
Current Diabetes Reviews Quantitative Ultrasound in Diagnosis of Metabolic Bone Diseases
Current Medical Imaging Effects of Physical Exercise on Depressive Symptoms and Biomarkers in Depression
CNS & Neurological Disorders - Drug Targets Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Current Psychopharmacology Transcranial Magnetic Stimulation of Degenerating Brain: A Comparison of Normal Aging, Alzheimer’s, Parkinson’s and Huntington's Disease
Current Alzheimer Research Impact of HIV on Regional & Cellular Organisation of the Brain
Current HIV Research Opinion Paper: A Cognitive-cultural Segregation and the Three Stages of Aging
Current Aging Science Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Inflammation in Parkinsons Diseases and Other Neurodegenerative Diseases: Cause and Therapeutic Implications
Current Pharmaceutical Design Intravenous Immunoglobulin Treatment Preserves and Protects Primary Rat Hippocampal Neurons and Primary Human Brain Cultures Against Oxidative Insults
Current Alzheimer Research Oral Chemotherapy in Elderly Women with Metastatic Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Diabetes Exacerbates Nanoparticles Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets A Rationale for Curcuminoids for the Prevention or Treatment of Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Mechanisms of Neurovascular Dysfunction in Acute Ischemic Brain
Current Medicinal Chemistry Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry Role of Mitochondrial Protein Quality Control in Oxidative Stress-induced Neurodegenerative Diseases
Current Alzheimer Research